EBS News and Press, Emergent Biosolutions Inc. From 08/04/22

The Biden administration declared the current monkeypox outbreak a public health emergency on Thursday in a bid to marshal resources and raise awareness to contain the fast-spreading virus. Previously, The Washington Post reported the government plans, citing two officials. “...

The Biden administration is expected to declare the current monkeypox outbreak a public health emergency as soon as Thursday, The Washington Post reported Thursday. The Health and Human Services Secretary Xavier Becerra is expected to make the announcement at an afternoon briefing...

President Joe Biden appointed two top federal officials to lead the U.S. response against monkeypox, the White House announced Tuesday, as the ongoing outbreak has prompted more states to declare emergencies to contain the virus. Robert Fenton, who currently serves as Regional Admin...

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...

Check Out These Three MonkeyPox Stocks Making Headlines In The Stock Market Today Unless you’ve been living under a rock, it’s likely you’ve seen all the monkeypox headlines in the stock market today. Health authorities worldwide are actively looking for a w...

Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q2 2022 Earnings Call Aug 01, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q2 2022 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q2 2022 Results Conference Call August 01, 2022 05:00 PM ET Company Participants Bob Burrows - Vice President of Investor Relations Bob Kramer - President and Chief Executive Officer Rich Lindahl - Chief Financial Officer Co...

Emergent BioSolutions ( NYSE: EBS ) swung to a Q2 2022 net loss of $56.4M after a $4.6M net gain in the prior-year period. Gross margin also fell to 28% from 39%. The Gaithersburg, Md.-based life sciences company's Q2 results also missed on the top and bottom lines ...

Emergent Biosolutions press release ( NYSE: EBS ): Q2 Non-GAAP EPS of -$0.86 misses by $1.26 . Revenue of $242.7M (-38.9% Y/Y) misses by $25.66M . FY2022 Outlook : Total revenues of $1.15B to $1.25B vs. consensus of $1.21B; Adjusted net income of -$15M to $...

Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segment Resumes financial guidance; provides update to full year 2022 outlook GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent Bi...